ReviewCancers2023
Diffuse Large B-Cell Lymphoma in the HIV Setting.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Lymphoma Related to the Ventricular System: A Rare Case Report and Systematic Review of Intraventricular Lymphomas.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Clinical Characteristics and Prognostic Analysis of EBV-Positive HIV-Associated Diffuse Large B-Cell Lymphoma in China: A Retrospective Single-Center Study.Current oncology (Toronto, Ont.) · 2026Article
- Mutational profiling of HIV+ diffuse large B-cell lymphoma reveals distinct mutational features with evidence of genomic instability.AIDS (London, England) · 2026Article
- Unmasking small-bowel DLBCL in an elderly patient with simultaneous multiple primary cancers through anemia: a case report and literature review.Frontiers in oncology · 2026Article
- HIV-Associated Diffuse Large B-Cell Lymphoma Treated With Outpatient Pola-R-CHP Without Antiretroviral Therapy Modification: A Case Report.Case reports in infectious diseases · 2026Article
- The Characteristics of Peripheral Blood Lymphocyte Subsets in HIV-related Diffuse Large B-cell Lymphoma Patients and Their Impact on Treatment Efficacy.Current HIV research · 2026Article
- A study comparing the efficacy of R-CHOP and R-DA-EPOCH regimens in young, high-risk treatment-naïve diffuse large B-cell lymphoma patients: a multicenter retrospective analysis.American journal of cancer research · 2026Article
- Spontaneous regression of stage IV advanced diffuse large B-cell lymphoma in an person living with HIV: a case report and literature review.Frontiers in oncology · 2026Article
- Research trends between acquired immune deficiency syndrome and hematological malignancies: a bibliometric analysis.Discover oncology · 2025Article
- Circulating Biomarker Panorama in HIV-Associated Lymphoma: A Bridge from Early Risk Warning to Prognostic Stratification.Biomolecules · 2025Review
- Shared genomic features of HIV+ diffuse large B-cell lymphoma in two African cohorts.Scientific reports · 2025Article
- Current State of AIDS-Related Malignant Lymphoma.Viruses · 2025Review
- Serum β2-microglobulin level is associated with the survival of HIV-associated diffuse large B-cell lymphoma: a retrospective study from China.Scientific reports · 2025Article
- Article
- Development of a novel prognostic nomogram for AIDS-associated diffuse large B-cell lymphoma: a retrospective study from northern China.Clinical and experimental medicine · 2025Article
- Case report of two patients with refractory HIV-related B-cell lymphoma treated with the monoclonal antibody glofitamab for secondary central nervous system involvement.Frontiers in oncology · 2025Article
- Diagnostic and therapeutic pathways for lymphoma patients: expert consensus through Nominal Group Technique and Delphi methodology.Frontiers in oncology · 2025Article
- Article
- Article
- Double-Hit Diffuse Large B-Cell Lymphoma in AIDS.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Despite the widespread use of combined antiretroviral therapy (cART) and the subsequent decrease in AIDS-defining cancers, HIV-related lymphomas remain a leading cause of morbidity and mortality in people with HIV (PWH). Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL) subtype in PWH. This lymphoma is a heterogeneous disease including morphological variants and molecular subtypes according to the cell of origin or the mutation profile. In the pre-cART era, treatment with standard-dose chemotherapy induced high rates of toxicity and outcomes were very poor. The introduction of cART and the incorporation of infection prophylaxis allowed the use of conventional intensive chemotherapy regimens used in the general population, such as R-CHOP or R-EPOCH. The use of cART during chemotherapy treatment was initially controversial due to the potential risk of adverse drug-drug interactions. However, the availability of current cART regimens with less potential to cause drug interactions and evidence that cART improves survival rates in NHL strongly support the use of cART in PWH with DLBCL. Consequently, interdisciplinary collaboration between HIV specialists and hemato-oncologists for the management of potential interactions and overlapping toxicities between antiretroviral and antineoplastic drugs is crucial for the optimal treatment of PWH with NHL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.